ERBB2 and breast cancer: Although the best method to assess HER2 status remains controversial, it is generally accepted that breast cancer patients with HER2 overexpression by IHC (3+) and gene amplification ratio of >2 by fluorescent in situ hybridization (FISH) were considered for adjuvant trastuzumab treatment [41].